Review



dmso plus isotype igg2α  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    Bio X Cell dmso plus isotype igg2α
    Timeless down-regulation potentiates erastin combined with anti-PD-1 therapy efficacy. (A) Experimental design for testing the combination of erastin and anti-PD-1 in an orthotopic LLC1 model. Ten days after orthotopic inoculation with 5 × 10 5 shCtrl or shTimeless LLC1 cells, tumor-bearing mice were treated for 20 days with the following regimens: DMSO + <t>IgG2α,</t> erastin (30 mg/kg i.p. daily) + IgG2α, DMSO + anti-PD-1 (200 μg i.p. every 3 days), or erastin + anti-PD-1. (B) Weights of lung tumors after treatment in the orthotopic LLC1 model ( shCtrl and shTimeless : DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1). (C) Mice body weight was monitored every 3 days ( n = 5). (D) Representative TEM images of mitochondria in lung tumors from orthotopic tumor-bearing mice transfected with shCtrl or shTimeless and treated with monotherapy or combination therapy. (E) Bar graphs illustrated the percentage of CD3e + T cells among CD45 + cells, CD4 + T cells among CD3e + T cells, and CD8 + T cells among CD3e + T cells in lung orthotopic tumors. (F) CD86 + (M1-like) and CD206 + (M2-like) macrophage proportions among CD11b + F4/80 + cells in lung orthotopic tumors. (G) Representative mIF images of LLC1 tumor tissues from the shCtrl and shTimeless groups treated with the indicated regimens: DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1. Staining shows Timeless (pink), 4HNE (yellow), Cd4 (purple), and Cd8 (green). Statistical analyses in (B), (E), and (F) were performed using a 2-tailed Student’s t test. Primary comparisons were made between each treatment group and the shCtrl + DMSO + IgG2α control. The significance is denoted above the bars. Further comparisons were conducted between the monotherapy and combination therapy groups, as well as between the shTimeless and shCtrl groups. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. Abbreviations: 4HNE, 4-hydroxyonenal; i.p., intraperitoneal; mIF, multiplex immunofluorescence; PD-1, programmed cell death protein 1; TEM, transmission electron microscopy.
    Dmso Plus Isotype Igg2α, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1784 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dmso+plus+isotype+igg2%CE%B1/InVivoMAb+rat+IgG2a+isotype+control%2C+anti-trinitrophenol/pmc12864654-195-17-21
    Average 98 stars, based on 1784 article reviews
    dmso plus isotype igg2α - by Bioz Stars, 2026-09
    98/100 stars

    Images

    1) Product Images from "TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy"

    Article Title: TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy

    Journal: Cancer Communications

    doi: 10.34133/cancomm.0009

    Timeless down-regulation potentiates erastin combined with anti-PD-1 therapy efficacy. (A) Experimental design for testing the combination of erastin and anti-PD-1 in an orthotopic LLC1 model. Ten days after orthotopic inoculation with 5 × 10 5 shCtrl or shTimeless LLC1 cells, tumor-bearing mice were treated for 20 days with the following regimens: DMSO + IgG2α, erastin (30 mg/kg i.p. daily) + IgG2α, DMSO + anti-PD-1 (200 μg i.p. every 3 days), or erastin + anti-PD-1. (B) Weights of lung tumors after treatment in the orthotopic LLC1 model ( shCtrl and shTimeless : DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1). (C) Mice body weight was monitored every 3 days ( n = 5). (D) Representative TEM images of mitochondria in lung tumors from orthotopic tumor-bearing mice transfected with shCtrl or shTimeless and treated with monotherapy or combination therapy. (E) Bar graphs illustrated the percentage of CD3e + T cells among CD45 + cells, CD4 + T cells among CD3e + T cells, and CD8 + T cells among CD3e + T cells in lung orthotopic tumors. (F) CD86 + (M1-like) and CD206 + (M2-like) macrophage proportions among CD11b + F4/80 + cells in lung orthotopic tumors. (G) Representative mIF images of LLC1 tumor tissues from the shCtrl and shTimeless groups treated with the indicated regimens: DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1. Staining shows Timeless (pink), 4HNE (yellow), Cd4 (purple), and Cd8 (green). Statistical analyses in (B), (E), and (F) were performed using a 2-tailed Student’s t test. Primary comparisons were made between each treatment group and the shCtrl + DMSO + IgG2α control. The significance is denoted above the bars. Further comparisons were conducted between the monotherapy and combination therapy groups, as well as between the shTimeless and shCtrl groups. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. Abbreviations: 4HNE, 4-hydroxyonenal; i.p., intraperitoneal; mIF, multiplex immunofluorescence; PD-1, programmed cell death protein 1; TEM, transmission electron microscopy.
    Figure Legend Snippet: Timeless down-regulation potentiates erastin combined with anti-PD-1 therapy efficacy. (A) Experimental design for testing the combination of erastin and anti-PD-1 in an orthotopic LLC1 model. Ten days after orthotopic inoculation with 5 × 10 5 shCtrl or shTimeless LLC1 cells, tumor-bearing mice were treated for 20 days with the following regimens: DMSO + IgG2α, erastin (30 mg/kg i.p. daily) + IgG2α, DMSO + anti-PD-1 (200 μg i.p. every 3 days), or erastin + anti-PD-1. (B) Weights of lung tumors after treatment in the orthotopic LLC1 model ( shCtrl and shTimeless : DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1). (C) Mice body weight was monitored every 3 days ( n = 5). (D) Representative TEM images of mitochondria in lung tumors from orthotopic tumor-bearing mice transfected with shCtrl or shTimeless and treated with monotherapy or combination therapy. (E) Bar graphs illustrated the percentage of CD3e + T cells among CD45 + cells, CD4 + T cells among CD3e + T cells, and CD8 + T cells among CD3e + T cells in lung orthotopic tumors. (F) CD86 + (M1-like) and CD206 + (M2-like) macrophage proportions among CD11b + F4/80 + cells in lung orthotopic tumors. (G) Representative mIF images of LLC1 tumor tissues from the shCtrl and shTimeless groups treated with the indicated regimens: DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1. Staining shows Timeless (pink), 4HNE (yellow), Cd4 (purple), and Cd8 (green). Statistical analyses in (B), (E), and (F) were performed using a 2-tailed Student’s t test. Primary comparisons were made between each treatment group and the shCtrl + DMSO + IgG2α control. The significance is denoted above the bars. Further comparisons were conducted between the monotherapy and combination therapy groups, as well as between the shTimeless and shCtrl groups. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. Abbreviations: 4HNE, 4-hydroxyonenal; i.p., intraperitoneal; mIF, multiplex immunofluorescence; PD-1, programmed cell death protein 1; TEM, transmission electron microscopy.

    Techniques Used: Transfection, Staining, Control, Multiplex Assay, Immunofluorescence, Transmission Assay, Electron Microscopy

    Related Articles

    Injection:

    Article Title: TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy
    Article Snippet: .. For combination therapy, mice injected with shCtrl and shTimeless LLC1 cells were randomized into 4 groups: (a) DMSO plus isotype IgG2α (BioXcell, Cat. BE0089, 200 μg, injected intraperitoneally on days 10, 13, 16, 19, 22, 25, and 28); (b) erastin (30 mg/kg, injected intraperitoneally daily) plus isotype IgG2α; (c) DMSO plus anti-PD-1 antibody (BioXcell, Cat. BE0146, 200 μg, injected intraperitoneally on days 10, 13, 16, 19, 22, 25, and 28); and (d) erastin plus anti-PD-1 antibody. ..



    Similar Products

    dmso plus isotype igg2α  (Bio X Cell)
    98
    Bio X Cell dmso plus isotype igg2α
    Timeless down-regulation potentiates erastin combined with anti-PD-1 therapy efficacy. (A) Experimental design for testing the combination of erastin and anti-PD-1 in an orthotopic LLC1 model. Ten days after orthotopic inoculation with 5 × 10 5 shCtrl or shTimeless LLC1 cells, tumor-bearing mice were treated for 20 days with the following regimens: DMSO + <t>IgG2α,</t> erastin (30 mg/kg i.p. daily) + IgG2α, DMSO + anti-PD-1 (200 μg i.p. every 3 days), or erastin + anti-PD-1. (B) Weights of lung tumors after treatment in the orthotopic LLC1 model ( shCtrl and shTimeless : DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1). (C) Mice body weight was monitored every 3 days ( n = 5). (D) Representative TEM images of mitochondria in lung tumors from orthotopic tumor-bearing mice transfected with shCtrl or shTimeless and treated with monotherapy or combination therapy. (E) Bar graphs illustrated the percentage of CD3e + T cells among CD45 + cells, CD4 + T cells among CD3e + T cells, and CD8 + T cells among CD3e + T cells in lung orthotopic tumors. (F) CD86 + (M1-like) and CD206 + (M2-like) macrophage proportions among CD11b + F4/80 + cells in lung orthotopic tumors. (G) Representative mIF images of LLC1 tumor tissues from the shCtrl and shTimeless groups treated with the indicated regimens: DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1. Staining shows Timeless (pink), 4HNE (yellow), Cd4 (purple), and Cd8 (green). Statistical analyses in (B), (E), and (F) were performed using a 2-tailed Student’s t test. Primary comparisons were made between each treatment group and the shCtrl + DMSO + IgG2α control. The significance is denoted above the bars. Further comparisons were conducted between the monotherapy and combination therapy groups, as well as between the shTimeless and shCtrl groups. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. Abbreviations: 4HNE, 4-hydroxyonenal; i.p., intraperitoneal; mIF, multiplex immunofluorescence; PD-1, programmed cell death protein 1; TEM, transmission electron microscopy.
    Dmso Plus Isotype Igg2α, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/dmso+plus+isotype+igg2%CE%B1/InVivoMAb+rat+IgG2a+isotype+control%2C+anti-trinitrophenol/pmc12864654-195-17-21
    Average 98 stars, based on 1 article reviews
    dmso plus isotype igg2α - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    Timeless down-regulation potentiates erastin combined with anti-PD-1 therapy efficacy. (A) Experimental design for testing the combination of erastin and anti-PD-1 in an orthotopic LLC1 model. Ten days after orthotopic inoculation with 5 × 10 5 shCtrl or shTimeless LLC1 cells, tumor-bearing mice were treated for 20 days with the following regimens: DMSO + IgG2α, erastin (30 mg/kg i.p. daily) + IgG2α, DMSO + anti-PD-1 (200 μg i.p. every 3 days), or erastin + anti-PD-1. (B) Weights of lung tumors after treatment in the orthotopic LLC1 model ( shCtrl and shTimeless : DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1). (C) Mice body weight was monitored every 3 days ( n = 5). (D) Representative TEM images of mitochondria in lung tumors from orthotopic tumor-bearing mice transfected with shCtrl or shTimeless and treated with monotherapy or combination therapy. (E) Bar graphs illustrated the percentage of CD3e + T cells among CD45 + cells, CD4 + T cells among CD3e + T cells, and CD8 + T cells among CD3e + T cells in lung orthotopic tumors. (F) CD86 + (M1-like) and CD206 + (M2-like) macrophage proportions among CD11b + F4/80 + cells in lung orthotopic tumors. (G) Representative mIF images of LLC1 tumor tissues from the shCtrl and shTimeless groups treated with the indicated regimens: DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1. Staining shows Timeless (pink), 4HNE (yellow), Cd4 (purple), and Cd8 (green). Statistical analyses in (B), (E), and (F) were performed using a 2-tailed Student’s t test. Primary comparisons were made between each treatment group and the shCtrl + DMSO + IgG2α control. The significance is denoted above the bars. Further comparisons were conducted between the monotherapy and combination therapy groups, as well as between the shTimeless and shCtrl groups. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. Abbreviations: 4HNE, 4-hydroxyonenal; i.p., intraperitoneal; mIF, multiplex immunofluorescence; PD-1, programmed cell death protein 1; TEM, transmission electron microscopy.

    Journal: Cancer Communications

    Article Title: TIMELESS Promotes LUAD Growth via Suppressing Transferrin-Mediated Ferroptosis and Reprograms the Tumor Microenvironment against Anti-PD-1 Immunotherapy

    doi: 10.34133/cancomm.0009

    Figure Lengend Snippet: Timeless down-regulation potentiates erastin combined with anti-PD-1 therapy efficacy. (A) Experimental design for testing the combination of erastin and anti-PD-1 in an orthotopic LLC1 model. Ten days after orthotopic inoculation with 5 × 10 5 shCtrl or shTimeless LLC1 cells, tumor-bearing mice were treated for 20 days with the following regimens: DMSO + IgG2α, erastin (30 mg/kg i.p. daily) + IgG2α, DMSO + anti-PD-1 (200 μg i.p. every 3 days), or erastin + anti-PD-1. (B) Weights of lung tumors after treatment in the orthotopic LLC1 model ( shCtrl and shTimeless : DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1). (C) Mice body weight was monitored every 3 days ( n = 5). (D) Representative TEM images of mitochondria in lung tumors from orthotopic tumor-bearing mice transfected with shCtrl or shTimeless and treated with monotherapy or combination therapy. (E) Bar graphs illustrated the percentage of CD3e + T cells among CD45 + cells, CD4 + T cells among CD3e + T cells, and CD8 + T cells among CD3e + T cells in lung orthotopic tumors. (F) CD86 + (M1-like) and CD206 + (M2-like) macrophage proportions among CD11b + F4/80 + cells in lung orthotopic tumors. (G) Representative mIF images of LLC1 tumor tissues from the shCtrl and shTimeless groups treated with the indicated regimens: DMSO + IgG2α, erastin + IgG2α, DMSO + anti-PD-1, and erastin + anti-PD-1. Staining shows Timeless (pink), 4HNE (yellow), Cd4 (purple), and Cd8 (green). Statistical analyses in (B), (E), and (F) were performed using a 2-tailed Student’s t test. Primary comparisons were made between each treatment group and the shCtrl + DMSO + IgG2α control. The significance is denoted above the bars. Further comparisons were conducted between the monotherapy and combination therapy groups, as well as between the shTimeless and shCtrl groups. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant. Abbreviations: 4HNE, 4-hydroxyonenal; i.p., intraperitoneal; mIF, multiplex immunofluorescence; PD-1, programmed cell death protein 1; TEM, transmission electron microscopy.

    Article Snippet: For combination therapy, mice injected with shCtrl and shTimeless LLC1 cells were randomized into 4 groups: (a) DMSO plus isotype IgG2α (BioXcell, Cat. BE0089, 200 μg, injected intraperitoneally on days 10, 13, 16, 19, 22, 25, and 28); (b) erastin (30 mg/kg, injected intraperitoneally daily) plus isotype IgG2α; (c) DMSO plus anti-PD-1 antibody (BioXcell, Cat. BE0146, 200 μg, injected intraperitoneally on days 10, 13, 16, 19, 22, 25, and 28); and (d) erastin plus anti-PD-1 antibody.

    Techniques: Transfection, Staining, Control, Multiplex Assay, Immunofluorescence, Transmission Assay, Electron Microscopy